MIM
FHTX icon

MetLife Investment Management’s Foghorn Therapeutics FHTX Stock Holding History

MetLife Investment Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.4K Sell
9,710
-9,433
-49% -$51.8K ﹤0.01% 2690
2025
Q4 		$103K Sell
19,143
-2,139
-10% -$9.7K ﹤0.01% 2585
2025
Q3 		$104K Sell
21,282
-321
-1% -$1.7K ﹤0.01% 2636
2025
Q2 		$102K Buy
+21,603
New +$90.3K ﹤0.01% 2532
2024
Q4 		– Sell
-15,898
Closed -$148K – 2827
2024
Q3 		$148K Buy
15,898
+8,958
+129% +$64.9K ﹤0.01% 2441
2024
Q2 		$39.9K Buy
+6,940
New +$41.3K ﹤0.01% 2790
2023
Q4 		– Sell
-11,445
Closed -$57.2K – 2841
2023
Q3 		$57.2K Hold
11,445
– – ﹤0.01% 2810
2023
Q2 		$80.6K Buy
+11,445
New +$80K ﹤0.01% 2802
2023
Q1 		– Sell
-13,632
Closed -$87K – 2801
2022
Q4 		$87K Hold
13,632
– – ﹤0.01% 2646
2022
Q3 		$117K Hold
13,632
– – ﹤0.01% 2596
2022
Q2 		$185K Hold
13,632
– – ﹤0.01% 2379
2022
Q1 		$208K Buy
13,632
+4,949
+57% +$67.9K ﹤0.01% 2333
2021
Q4 		$199K Hold
8,683
– – ﹤0.01% 2056
2021
Q3 		$121K Buy
+8,683
New +$96.1K ﹤0.01% 2353

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

MetLife Investment Management's FHTX Position: Q1 2026 in Review

MetLife Investment Management reduced its Foghorn Therapeutics (FHTX) stake by 49% in Q1 2026, selling an estimated $51.8K and leaving 9,710 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2690.

MetLife Investment Management first reported a position in FHTX in Q3 2021 and has held it in 14 quarters since. The position peaked at $208K in Q1 2022. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • MetLife Investment Management held 9,710 shares of Foghorn Therapeutics worth $46.4K as of Q1 2026.
  • MetLife Investment Management sold 9,433 Foghorn Therapeutics shares in Q1 2026, an estimated $51.8K.
  • Foghorn Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2690 holding.
  • MetLife Investment Management first reported a position in Foghorn Therapeutics in Q3 2021 and has held it in 14 quarters since.
  • MetLife Investment Management's Foghorn Therapeutics position peaked at $208K in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.